We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.66 | -1.78% | 91.42 | 91.41 | 91.43 | 94.03 | 91.42 | 93.99 | 322,680 | 10:51:20 |
From May 2021 to May 2024
By Colin Kellaher
Shares of Translate Bio Inc. jumped nearly 30% in premarket trading Tuesday after the messenger RNA therapeutics company agreed to be acquired by vaccine collaboration partner Sanofi SA for about $3.2 billion.
France's Sanofi said it would pay $38 a share in cash for Translate Bio, a roughly 30% premium to Monday's closing price of $29.15 for the Lexington, Mass., company.
Sanofi and Translate Bio, which in 2018 signed a collaboration and exclusive license agreement to develop mRNA vaccines, said they expect the deal to close in the third quarter.
Translate Bio shares were recently up 29% to $37.63 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 03, 2021 06:37 ET (10:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
